<DOC>
	<DOCNO>NCT02982434</DOCNO>
	<brief_summary>The aim prospective randomize double-blind study compare efficacy new pharmaceutical composition contain botulinum toxin injection epicardial fat pad prevent recurrence atrial tachyarrhythmia patient paroxysmal atrial fibrillation undergo coronary artery bypass grafting .</brief_summary>
	<brief_title>The New Pharmaceutical Composition Containing Botulinum Toxin Treat Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Patients paroxysmal AF ( recurrent episode least 2 year , â‰¥ 6 episode last 6 month ) At least one failed antiarrhythmic drug Indication cardiac surgery ( e.g . coronary artery bypass grafting , valve repair/replacement ) accord American College Cardiology/American Heart Association ( ACC/AHA ) guideline cardiac surgery Previous heart surgery atrial fibrillation ablation procedure Emergency coronary artery bypass graft Unstable angina heart failure Persistent atrial fibrillation atrial fibrillation time screen Planned maze procedure pulmonary vein isolation Unwillingness participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>botulinum toxin</keyword>
	<keyword>ischemic heart disease</keyword>
</DOC>